WO2002068399A1 - Derives d'arylcarbamates, preparation et utilisations - Google Patents
Derives d'arylcarbamates, preparation et utilisations Download PDFInfo
- Publication number
- WO2002068399A1 WO2002068399A1 PCT/FR2002/000668 FR0200668W WO02068399A1 WO 2002068399 A1 WO2002068399 A1 WO 2002068399A1 FR 0200668 W FR0200668 W FR 0200668W WO 02068399 A1 WO02068399 A1 WO 02068399A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbamate
- piperazino
- ethoxyphenyl
- formula
- ethyl
- Prior art date
Links
- 0 CCCN(CC**CCOC(NCc1c(*CC)cccc1)=O)c1cc(C(*)C(F)F)c2[s]cc(C(*C)=O)c2n1 Chemical compound CCCN(CC**CCOC(NCc1c(*CC)cccc1)=O)c1cc(C(*)C(F)F)c2[s]cc(C(*C)=O)c2n1 0.000 description 4
- PUGBGLLOYFVKMK-UHFFFAOYSA-N CCOc(cccc1)c1NC(OCCCN(CC1)CCN1c(cc1)nnc1Cl)=O Chemical compound CCOc(cccc1)c1NC(OCCCN(CC1)CCN1c(cc1)nnc1Cl)=O PUGBGLLOYFVKMK-UHFFFAOYSA-N 0.000 description 1
- MJRGADZVTTYMFI-UHFFFAOYSA-N CCOc(cccc1)c1NC(OCCCN(CC1)CCN1c1c(C)ccc(C)c1)=O Chemical compound CCOc(cccc1)c1NC(OCCCN(CC1)CCN1c1c(C)ccc(C)c1)=O MJRGADZVTTYMFI-UHFFFAOYSA-N 0.000 description 1
- CKDNIYMHJSOPGR-UHFFFAOYSA-N CCOc(cccc1)c1NC(OCCN(CC1)CCN1c1ncccn1)=O Chemical compound CCOc(cccc1)c1NC(OCCN(CC1)CCN1c1ncccn1)=O CKDNIYMHJSOPGR-UHFFFAOYSA-N 0.000 description 1
- FFDNPFGRYMMJQV-UHFFFAOYSA-N COc(cccc1)c1NC(OCCCN1CCN(Cc2ccccc2)CC1)=O Chemical compound COc(cccc1)c1NC(OCCCN1CCN(Cc2ccccc2)CC1)=O FFDNPFGRYMMJQV-UHFFFAOYSA-N 0.000 description 1
- MIFYYGJMTLEQRW-UHFFFAOYSA-N COc(cccc1)c1NC(OCCN(CC1)CCN1c(cc1)nnc1Cl)=O Chemical compound COc(cccc1)c1NC(OCCN(CC1)CCN1c(cc1)nnc1Cl)=O MIFYYGJMTLEQRW-UHFFFAOYSA-N 0.000 description 1
- CBZHCTBJPVSWAM-UHFFFAOYSA-N COc(cccc1)c1NC(OCCN(CC1)CCN1c1cccc(C(F)(F)F)c1)=O Chemical compound COc(cccc1)c1NC(OCCN(CC1)CCN1c1cccc(C(F)(F)F)c1)=O CBZHCTBJPVSWAM-UHFFFAOYSA-N 0.000 description 1
- VPHPPHFGQBQZPM-UHFFFAOYSA-N COc(cccc1)c1NC(OCCN(CC1)CCN1c1ncccn1)=O Chemical compound COc(cccc1)c1NC(OCCN(CC1)CCN1c1ncccn1)=O VPHPPHFGQBQZPM-UHFFFAOYSA-N 0.000 description 1
- UNSHYRWKYQEYGB-UHFFFAOYSA-N Cc(cc1)ccc1N1CCN(CCCOC(Nc(cccc2)c2OC)=O)CC1 Chemical compound Cc(cc1)ccc1N1CCN(CCCOC(Nc(cccc2)c2OC)=O)CC1 UNSHYRWKYQEYGB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/42—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms with nitro or nitroso radicals directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to new compounds, their preparation and their uses, in particular therapeutic. It relates more particularly to compounds derived from arylcarbamates, to their preparation and to their uses, in particular in the field of human or animal health.
- the compounds according to the invention are preferably ligands of the 5-HT4 serotoninergic receptors, and are therefore usable in the therapeutic or prophylactic treatment of any disorder involving a 5-HT4 receptor.
- the present invention also relates to pharmaceutical compositions comprising such compounds, their preparation and their uses, as well as methods of treatment using said compounds.
- the present invention relates to arylcarbamate derivatives of general formula (I) and their pharmacologically acceptable salts. They are preferably compounds capable of interfering with processes dependent on serotonin, even more preferably ligands of 5-HT4 receptors, in particular of human serotype.
- the invention thus provides methods of treatment or prophylaxis of any disorder involving a 5-HT4 receptor.
- the compounds and compositions according to the invention can prove to be useful for the prophylactic or therapeutic treatment of various pathologies such as:
- GFD gastroesophageal reflux disease
- irritable bowel syndrome various gastrointestinal disorders such as gastroesophageal reflux disease (GERD), irritable bowel syndrome, functional dyspepsia, gastroparesis, disorders related to gastrointestinal motility, nausea and constipation
- disorders of the central nervous system such as anxiety, pain, schizophrenia, depression, memory impairment and dementia heart conditions such as atrial fibrillation, arrhythmia and tachycardia genitourinary conditions such as urinary retention, incontinence.
- a first subject of the invention resides in compounds of general formula (I):
- - Ri represents a lower alkyl or lower arylalkyl group
- R 2 represents the hydrogen atom or a lower alkyl group
- R 3 represents an aryl group or a heterocycle, chosen from phenyl, naphthyl, thienyl, furyl, pyridyl, pyrimidinyl, pyridazinyl, pirazinyl, this group being optionally substituted by one or more groups chosen from halogeno, alkoxy, cyano, hydroxy, nitro , alkyl, haloalkyl, alkylthio, -NHR 8 , -NHCOR 8 , -
- Y represents a bond or an alkylene chain, linear or branched, of 2 to 5 carbon atoms
- - J represents a group CR or the nitrogen atom
- - G represents a group CR 5 or the nitrogen atom
- R 4 , R 5 , R 6 and R taken individually represent the hydrogen atom, a halogen atom, a lower alkyl group, an alkoxy group, alkylthio, alkylsulfonyl, alkylsulfoxide, trifluoromethyl, nitro, cyano, carboxy, carboxyalkyl, alkylamino or dialkylamino, - R 8 and R represent the hydrogen atom, an aryl group or a lower alkyl group, or, when G or J are not the nitrogen atom, the groups ORi and R 7 and / or the groups Ré and R 7 and / or the groups R ⁇ s and R 5 and / or the groups R 5 and j can form, taken together with the aromatic nucleus to which they are attached, a saturated or unsaturated cycle, n is 1 or 2,
- - Y represents a 1- (rnethoxymethyl) ethyl or 2-hydroxypropyl radical
- R represents a phenyl or 2-methoxyphenyl group
- Ri represents a lower alkyl group
- R 2 , R 4 and R 6 represent a hydrogen atom
- G and J represent a CH group and n is equal to 1
- lower alkyl more particularly designates a linear or branched hydrocarbon radical having from 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, neopentyl, n- hexyl.
- C ⁇ -C 4 groups are preferred.
- Methyl and ethyl groups are particularly preferred.
- aryl groups are mono-, bi- or tri-cyclic aromatic hydrocarbon systems having from 6 to 18 carbon atoms. Mention may in particular be made of the phenyl or naphthyl radical.
- alkylene groups within the meaning of the invention are divalent groups corresponding to the alkyl groups as defined above by removal of a hydrogen atom.
- alkoxy groups correspond to the alkyl groups defined above linked to the nucleus via an —O— (ether) bond.
- alkylthio groups correspond to the alkyl groups defined above linked to the nucleus via a -S- (thioether) bond.
- halogen is meant a fluorine, chlorine, bromine or iodine atom.
- haloalkyl is meant an alkyl radical as defined above in leuqel one or more hydrogen atoms have been replaced by one or more halogen atom. Mention may in particular be made of the trifluoromethyl radical.
- heteroatom is meant an atom chosen from O, N and S.
- Arylalkyl groups are groups comprising an aryl residue as defined above linked to the nucleus by means of an alkylene chain.
- the groups ORi and R 7 and / or the groups R 6 and R 7 and / or the groups R ⁇ and R 5 and / or the groups R 5 and R 4 form together with the aromatic nucleus to which they are attached, a saturated cycle or not, it is preferably a ring comprising from 3 to 8 atoms, aromatic or not, optionally comprising one or more heteroatoms, preferably 0 to 3.
- Preferred examples of such rings are in particular benzonirane, dihydrobenzofuran, benzodioxane, benzopyrane, dihydrobenzopyrane, benzodioxole.
- these different groups may or may not carry one or more substituents, chosen for example from halogen, nitro, cyano, trifluoromethyl, carboxy, (C ⁇ -C 6 ) -alkoxycarbonyl, mono- or di- ( C ⁇ -C 6 ) -alkylaminocarbonyl, aminocarbonyl, mono- or di- (C 6 -C ⁇ 2 ) -aryl- or hetero- (C 2 -C 12 ) -arylaminocarbonyl, mono- or di- (C 6 -C 12 ) -aryl- or hetero- (C 2 -C 12 ) -aryl- (C 1 -C 6 ) -alkylaminocarbonyl, hydroxy, alkoxy, (C 1 -C 6 ) -alkyl, amino optionally substituted by one or more groups chosen from (C ⁇ -C 6 ) -alkyl, (C 3 -C 8 ) -cycloalkyle, (
- the compounds of the present invention exhibit excellent selectivity for the 5-HT 4 receptor with respect to the other 5-HT receptor subtypes and in particular with respect to the 5-HT3 receptor.
- the compound 2- [4- (4-pyridinyl) piperazino] ethyl- N- (2-methoxyphenyl) carbamate (63) has a Ki of 5 nM on the 5-HT 4 receptor and no activity until the concentration of 1 ⁇ M on the 5-HT ⁇ A , 5-HT IB , 5- HT 2A , 5-HT 2C , 5-HT 3 , 5-HT 5A , 5-HT 6 and 5-HT 7 receptors.
- the compounds of the present invention do not have any side effects, such as serious cardiovascular complications, unlike other known ligands 5-HT4 or 5-HT3, such as Cisapride.
- Preferred compounds within the meaning of the invention are compounds of formula (I) above in which:
- - RI represents a methyl or ethyl group, and / or
- R3 represents an aryl or heterocycle group with 6 atoms, optionally substituted, preferably containing one or two nitrogen atoms, or an optionally substituted phenyl group, and / or
- - Y is an alkylene chain of 2 or 3 carbon atoms, preferably linear, and / or
- R 2 is a hydrogen atom, and / or
- - R is a hydrogen atom, and / or - R is a hydrogen atom, and / or
- - G is a CH group, and / or
- - J is a CH group.
- a preferred sub-family within the meaning of the invention is represented by the compounds of formula (I) in which RI represents a methyl or ethyl group. As illustrated in the examples, such derivatives within the meaning of the invention have advantageous properties as ligands for 5-HT4 receptors.
- a particularly preferred family is that in which RI represents a methyl or ethyl group.
- R3 represents a heterocycle with 6 atoms, optionally substituted, containing one or two nitrogen atoms or an optionally substituted phenyl group.
- the subject of the invention is the compounds of formula (I) in which RI represents a methyl or ethyl group and R3 represents an optionally substituted phenyl group.
- the invention relates to the compounds of formula (I) in which RI represents a methyl or ethyl group and R3 a heterocycle with 6 atoms, optionally substituted, containing one or two nitrogen atoms.
- a particular family according to the invention is represented by the compounds of general formula (I) as defined above, and the sub-families indicated above, in which R 2 is a hydrogen atom, and / or R is a hydrogen atom, and / or R 6 is a hydrogen atom, even more preferably in which at least two of the groups R 2 , R 4 and R e are a hydrogen atom, even more preferably in which the three groups R 2 , R and R e each represent a hydrogen atom.
- Another particular family according to the invention is represented by the compounds of general formula (I) as defined above, and the sub-families indicated above, in which G is the group CH and / or J is the group CH, more preferably in which G and J each represent the group CH.
- Another particular family according to the invention is represented by the compounds of general formula (I) as defined above, and the sub-families indicated above, in which n equals 1.
- Another particular family according to the invention is represented by the compounds of general formula (I) as defined above, and the sub-families indicated above, in which Y is an alkylene chain of 2 or 3 carbon atoms , preferably unbranched.
- the compounds of the invention may be in the form of salts, in particular basic or acid addition salts, preferably compatible with pharmaceutical use.
- the compounds of formula (I) can be prepared according to techniques known to those skilled in the art.
- the present invention describes in this regard various synthetic routes, which are illustrated in FIGS. 1-5 and in the examples, and can be implemented by a person skilled in the art, as indicated in the examples.
- the starting compounds can be obtained commercially or synthesized according to usual methods. It is understood that the present application is not limited to a particular synthetic route, and extends to other methods allowing the production of the indicated compounds.
- the compounds of formula (I) can be synthesized either in the liquid phase according to diagrams 1 -4 ( Figures 1 -4), or in parallel synthesis on solid support according to diagram 5 ( Figure 5).
- the invention resides in a process for the preparation of a compound as defined above, characterized in that a product of formula (II) is reacted with a product of formula (III):
- a carbonyl donor reagent preferably the (Boc) 2 O / system DMAP
- the product obtained is recovered.
- the reaction is advantageously carried out in a solvent, for example neutral, typically an aprotic solvent (see FIG. 1).
- Another particular object of the invention resides in a process for the preparation of a compound as defined above, characterized in that a product of formula (II) is reacted with a product of formula (III) in which groups RI, R2, R3, R4, R6, Y, J, G and n have the same meaning as above, in a CXCl 2 / pyridine system, and the product obtained is recovered.
- the reaction is advantageously carried out in a solvent, for example neutral, typically an aprotic solvent (see FIG. 2).
- Another particular object of the invention resides in a process for the preparation of a compound as defined above, characterized in that a product of formula (II) is reacted with a product of formula (XVI) and a product of formula (XVII), in which the groups RI, R2, R3, R4, R6, Y, J, G and n have the same meaning as above, and the product obtained is recovered.
- the reaction is advantageously carried out in the presence of Et 2 O (see FIG. 3).
- Another particular object of the invention resides in a process for the preparation of a compound as defined above, characterized in that a product of formula is reacted
- the invention relates to a process for the preparation of a compound as defined above, characterized in that a product of formula (XIV) is reacted with a product of formula (XII):
- spacer group K corresponds to the formula (XV) below:
- the process advantageously comprises the preparation of the compound of formula (XIV) (or of formula (XI)) according to the reaction scheme presented in FIG. 5.
- Another subject of the present invention relates to any pharmaceutical composition comprising a compound as defined above. It is advantageously a pharmaceutical composition for the treatment or prophylaxis of diseases in which a 5-HT4 receptor is involved, for example the 5-HT4e receptor.
- the pharmaceutical compositions according to the invention can be used in particular for the treatment or prophylaxis of gastrointestinal disorders, central nervous system disorders, heart conditions or genitourinary conditions.
- the invention also relates to the use of a compound as defined above for the preparation of a pharmaceutical composition intended for the implementation of a method of treatment or prophylaxis of the human or animal body.
- the invention also relates to a method of treating a pathology in which a 5-HT4 receptor is involved, comprising the administration to a subject, in particular a human, of an effective dose of a compound or of a pharmaceutical composition such as defined above.
- compositions according to the invention advantageously comprise one or more excipients or vehicles, acceptable from the pharmaceutical point of view. Mention may be made, for example, of saline, physiological, isotonic, buffered solutions, etc., compatible with pharmaceutical use and known to those skilled in the art.
- the compositions may contain one or more agents or vehicles chosen from dispersants, solubilizers, stabilizers, preservatives, etc. Agents or vehicles which can be used in formulations (liquids and / or injectables and / or solids) are in particular methylcellulose, hydroxymethylcellulose, carboxymethylcellulose, polysorbate 80, mannitol, gelatin, lactose, vegetable oils, acacia, etc.
- compositions can be formulated in the form of an injectable suspension, gels, oils, tablets, suppositories, powders, capsules, capsules, etc., optionally by means of dosage forms or devices ensuring sustained and / or delayed release.
- an agent such as cellulose, carbonates or starches is advantageously used.
- the compounds or compositions according to the invention can be administered in different ways and in different forms.
- they can be injected systemically or orally, preferably systemically, such as for example intravenously, intramuscularly, subcutaneously, trans-dermal, intra-arterial, etc.
- the compounds are generally packaged in the form of liquid suspensions, which can be injected using syringes or infusions, for example. It is understood that the flow rate and / or the dose injected can be adapted by a person skilled in the art depending on the patient, pathology, method of administration, etc.
- the compounds are administered in doses which can vary between 0.1 ⁇ g and 100 mg / kg of body weight, more generally from 0.01 to 10 mg / kg, typically between 0.1 and 10 mg / kg.
- doses which can vary between 0.1 ⁇ g and 100 mg / kg of body weight, more generally from 0.01 to 10 mg / kg, typically between 0.1 and 10 mg / kg.
- repeated injections can be given, if necessary.
- the compositions according to the invention can also comprise other agents or active principles.
- FIG. 1 Synthesis diagram 1 of compounds according to the invention. Y, G, J and the groups Rl-
- R9 have the same definitions as before.
- R9 have the same definitions as before.
- R9 have the same definitions as before.
- the compounds of the invention were obtained using conventional organic synthesis and parallel synthesis methods.
- NMR spectra ! H and 13 C were recorded on an AC-200-Briicker spectrometer. The chemical shifts are given in ppm with tetramethylsilane taken as internal reference.
- the symbols, m, s, si, d, t, q, quint., Dd, td, etc mean respectively multiplet, singlet, broad singlet, doublet, triplet, quadruplet, quintuplet, doubled doubled, doubled triplet.
- the infrared spectra were recorded on a Perkin Elmer 841 device (KBr pellets) or on a Brucker vector 22 device with Fourier transform. The melting points were measured on a Kofler bench.
- HPLC spectra were carried out on a Shimadzu SCL10A device and an Uptisphere UP50DB-5m Cl 8 column (4.6 x50 mm) with a flow rate of 4 ml / min and at the wavelength of 220 nm.
- the products used for the preparation of the compounds of formula (I) are commercial and have been used without preliminary purification.
- the experimental protocols below are in no way limiting and are given by way of illustration. Unless otherwise stated, the percentages given are expressed by weight.
- Example 6 tert-butyl N- ⁇ 4- [allyl (dimethyl) silyl] -2-ethoxyphenyl ⁇ carbamate 7
- Cut-off Cut-off is carried out in 2 ml of TF A / reactor at room temperature for 2 hours. It is filtered, the resins are rinsed with 2x 2 ml of CH 2 C1 2 , the filtrates are concentrated under vacuum.
- the 48 mixtures are individually taken up in 8 ml of a CH 2 Cl 2 / HO 1: 1 mixture in Whatman 12 ml cartridges fitted with a PTFE filter.
- the pH of the aqueous phase is then adjusted to basic pH by the addition of an aqueous solution saturated with Na 2 CO 3 .
- the aqueous phase is then extracted with CH 2 C1 2 (1x 4ml then 1x 2ml).
- the cation exchange resin used is a BCX resin packaged by Bodhan (Mettler-Toledo) in the form of SPE cartridges of 1 g.
- the resin is firstly washed with 2x 3 ml of MeOH (packaging).
- the column is then washed with 2x 3 ml of MeOH (washing).
- the piperazine derivative is finally released by elution with 3 ml of a 2 M NH OH / MeOH solution (elution).
- the latter filtrate is concentrated under vacuum.
- the cleavage is carried out in 2 ml of TFA / reactor at room temperature for 2 hours. Filter, rinse the resins with 2x 2ml of CH 2 C1 2 , concentrate the filtrates. Each filtrate is then taken up in 1 ml of MeOH, the pH is adjusted to 9 with a 1 M aqueous solution of NaOH. The mixtures are then purified on cation exchange resin according to the protocol described above. The 44 filtrates recovered in previously tared tubes are concentrated under vacuum (Génévac) and analyzed by HPLC / MS before being weighed.
- Example 16 Biological results: The compounds of the invention were evaluated by measuring their affinity constant Ki carried out by displacement of a [ 3 H] radio-ligand -GR113808 on rat glial cells stably expressing the human isoform h5 -HT 4th
- the confluent glial cells are washed twice with PBS and centrifuged for 5 min at 300 g. The pellet is used immediately and the cells are suspended in 10 volumes of HEPES (50 mM, pH 7.4, 4 ° C) then homogenized with a teflon and centrifuged 20min at 40000g. The pellet is suspended again in 15 volumes of HEPES.
- HEPES 50 mM, pH 7.4, 4 ° C
- the displacement experiments are carried out in 500 ⁇ l of buffer (HEPES 50 mM) containing 20 ⁇ l of radio-ligand [ 3 H] -GR113808 at a concentration of 0.2 nM por the isoform h5-HT e or at a concentration equal to half the Kd radio-ligand for the other isoforms expressed in COS cells, 20 ⁇ l of competitive ligand at 7 variable concentrations and 50 ⁇ l of membrane preparation (100-200 ⁇ g of proteins determined by assay according to the Bradford method).
- the binding is carried out at 25 ° C. for 30 min and the reaction is stopped by rapid vacuum filtration (Brandel Harvester) on Whatman GF / B filters preincubated in a 0.1% PEI solution in order to reduce the non-specific binding.
- the radioactivity bound to the membranes is retained by the filter which is cut up and then washed with a cold buffer (50mM Tris-HCl, pH 7.4) and incubated overnight in 4 ml of scintillation liquid.
- the radioactivity is measured using a liquid scintillation counter (Beckmman LS 6500C).
- the binding data are obtained by computer-assisted linear regression (Graph Prism Program, Graph Pad Software. Inc; San Diego, CA) The results in the following table are given by way of example:
- 3-piperazinobenzonitrile 5 In 3 ml of DMSO are dissolved 6.7 g (77.66 mmol, 5.5 eq) of piperazine. 1.5 ml (14.12 mmol) of 3-fluorobenzonitrile are then added. The mixture is heated at 100 ° C for 60h. After cooling to room temperature, the reaction medium is poured into 126 ml of water. The precipitate formed is filtered and the filtrate is extracted with Et 2 O. After drying (MgSO 4 ) and concentration under vacuum, the crude product is purified by chromatography on 0 column (eluent CH 2 Cl 2 / MeOH 9: 1) to give 1, 39 g of the expected compound in the form of a pale yellow oil (yield 52%).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Indole Compounds (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002567913A JP2004529106A (ja) | 2001-02-23 | 2002-02-22 | 新規なアリールカルバマート誘導体、その製造および使用 |
HU0303253A HUP0303253A2 (hu) | 2001-02-23 | 2002-02-22 | Aril-karbamát-származékok, eljárás előállításukra és alkalmazásuk |
IL15704302A IL157043A0 (en) | 2001-02-23 | 2002-02-22 | Aryl carbamate derivatives, preparation and use thereof |
AU2002238688A AU2002238688B2 (en) | 2001-02-23 | 2002-02-22 | Aryl carbamate derivatives, preparation and use thereof |
US10/467,932 US7238693B2 (en) | 2001-02-23 | 2002-02-22 | Aryl carbamate derivatives, preparation and use thereof |
CA002438828A CA2438828A1 (fr) | 2001-02-23 | 2002-02-22 | Derives d'arylcarbamates, preparation et utilisations |
EP02704884A EP1362041A1 (fr) | 2001-02-23 | 2002-02-22 | Derives d'arylcarbamates, preparation et utilisations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0102431A FR2821356A1 (fr) | 2001-02-23 | 2001-02-23 | Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations |
FR01/02431 | 2001-02-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002068399A1 true WO2002068399A1 (fr) | 2002-09-06 |
WO2002068399B1 WO2002068399B1 (fr) | 2003-02-20 |
Family
ID=8860329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2002/000668 WO2002068399A1 (fr) | 2001-02-23 | 2002-02-22 | Derives d'arylcarbamates, preparation et utilisations |
Country Status (9)
Country | Link |
---|---|
US (1) | US7238693B2 (fr) |
EP (1) | EP1362041A1 (fr) |
JP (1) | JP2004529106A (fr) |
AU (1) | AU2002238688B2 (fr) |
CA (1) | CA2438828A1 (fr) |
FR (1) | FR2821356A1 (fr) |
HU (1) | HUP0303253A2 (fr) |
IL (1) | IL157043A0 (fr) |
WO (1) | WO2002068399A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018436A2 (fr) * | 2002-08-23 | 2004-03-04 | Cerep | Composes derives d'arylcarbamates, preparation et utilisations |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
WO2020198526A2 (fr) * | 2019-03-27 | 2020-10-01 | St. Jude Children's Research Hospital | Modulateurs à petites molécules de pank |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003725A1 (fr) * | 1991-08-20 | 1993-03-04 | Smithkline Beecham Plc | Antagonistes du recepteur 5-ht4 |
WO1993010742A2 (fr) * | 1991-11-27 | 1993-06-10 | Novo Nordisk A/S | Composes chimiques, leur preparation et leur utilisation |
WO1993020071A1 (fr) * | 1992-03-31 | 1993-10-14 | Glaxo Group Limited | Phenylurees et phenylcarbamates substitues, leur preparation, et leur utilisation comme antagonistes de 5-ht |
WO1995025100A1 (fr) * | 1994-03-14 | 1995-09-21 | Sanofi | Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes |
WO1995031449A1 (fr) * | 1994-05-17 | 1995-11-23 | Sanofi | Nouveaux esters de 3,5-dimethylpiperidin-1-ylalkyle |
SK278217B6 (en) * | 1993-07-29 | 1996-04-03 | Lucia Cernuskova | 3£4-(2-methoxyphenyl)-1-piperazinyl|-2-hydroxy-1-propylesters of alkoxyphenyl-carbame acids and method of preparation thereof |
SK278216B6 (en) * | 1993-07-29 | 1996-04-03 | Lucia Cernuskova | 3-(4-phenyl-1-piperazinyl)-2-hydroxy-1-propylesters of alkoxyphenyl-carbamic acids and method of preparation thereof |
US5605896A (en) * | 1992-02-25 | 1997-02-25 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1561023A (en) * | 1977-04-22 | 1980-02-13 | Beecham Group Ltd | 2-methoxy - 5 - chloro aniline derivatives |
KR930005004B1 (ko) * | 1985-04-15 | 1993-06-11 | 쟈안센 파아마슈우티카 엔. 부이. | 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법 |
DK203990D0 (da) * | 1990-08-24 | 1990-08-24 | Novo Nordisk As | Piperazinylderivater |
CA2123728A1 (fr) * | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Derives de l'uree et leur utilisation comme inhibiteurs de l'acat |
US5576335A (en) * | 1994-02-01 | 1996-11-19 | Nisshin Flour Milling Co., Ltd. | Urea derivatives and their use as ACAT inhibitors |
IL125658A0 (en) * | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
WO1999025687A1 (fr) * | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Inhibiteur de metalloprotease a base d'acide hydroxamique aromatique sulfone |
US6531477B1 (en) * | 1998-10-13 | 2003-03-11 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
WO2000029377A1 (fr) * | 1998-11-17 | 2000-05-25 | F. Hoffmann-La Roche Ag | Antagonistes iii du recepteur 4-aroyl-piperidin-ccr-3 |
CN1158256C (zh) * | 1998-11-20 | 2004-07-21 | 霍夫曼-拉罗奇有限公司 | 吡咯烷衍生物-ccr-3受体拮抗剂 |
EP1156807A4 (fr) * | 1998-12-18 | 2002-04-03 | Du Pont Pharm Co | N-ureidoalkyl-piperidines utilisees en tant que modulateurs de l'activite des recepteurs des chimiokines |
FR2788775B1 (fr) * | 1999-01-22 | 2001-04-13 | Pf Medicament | Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique |
AU7556000A (en) * | 1999-10-05 | 2001-05-10 | Takeda Chemical Industries Ltd. | Urea compounds, process for producing the same and use thereof |
-
2001
- 2001-02-23 FR FR0102431A patent/FR2821356A1/fr not_active Withdrawn
-
2002
- 2002-02-22 HU HU0303253A patent/HUP0303253A2/hu unknown
- 2002-02-22 AU AU2002238688A patent/AU2002238688B2/en not_active Ceased
- 2002-02-22 WO PCT/FR2002/000668 patent/WO2002068399A1/fr active IP Right Grant
- 2002-02-22 JP JP2002567913A patent/JP2004529106A/ja active Pending
- 2002-02-22 CA CA002438828A patent/CA2438828A1/fr not_active Abandoned
- 2002-02-22 US US10/467,932 patent/US7238693B2/en not_active Expired - Fee Related
- 2002-02-22 EP EP02704884A patent/EP1362041A1/fr not_active Withdrawn
- 2002-02-22 IL IL15704302A patent/IL157043A0/xx unknown
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993003725A1 (fr) * | 1991-08-20 | 1993-03-04 | Smithkline Beecham Plc | Antagonistes du recepteur 5-ht4 |
WO1993010742A2 (fr) * | 1991-11-27 | 1993-06-10 | Novo Nordisk A/S | Composes chimiques, leur preparation et leur utilisation |
US5605896A (en) * | 1992-02-25 | 1997-02-25 | Recordati S.A., Chemical And Pharmaceutical Company | Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities |
WO1993020071A1 (fr) * | 1992-03-31 | 1993-10-14 | Glaxo Group Limited | Phenylurees et phenylcarbamates substitues, leur preparation, et leur utilisation comme antagonistes de 5-ht |
EP0972773A1 (fr) * | 1992-03-31 | 2000-01-19 | Glaxo Group Limited | Dérivés de 2-oxadiazolyl- ou 2-thiadiazolyl-phénylcarbamate et -phenylurée, leur préparation et leur utilisation comme produits intermédiaires |
SK278217B6 (en) * | 1993-07-29 | 1996-04-03 | Lucia Cernuskova | 3£4-(2-methoxyphenyl)-1-piperazinyl|-2-hydroxy-1-propylesters of alkoxyphenyl-carbame acids and method of preparation thereof |
SK278216B6 (en) * | 1993-07-29 | 1996-04-03 | Lucia Cernuskova | 3-(4-phenyl-1-piperazinyl)-2-hydroxy-1-propylesters of alkoxyphenyl-carbamic acids and method of preparation thereof |
WO1995025100A1 (fr) * | 1994-03-14 | 1995-09-21 | Sanofi | Utilisation d'esters de l'acide 4-amino-5-chloro-2-methoxybenzoique comme 5-ht4 agonistes |
WO1995031449A1 (fr) * | 1994-05-17 | 1995-11-23 | Sanofi | Nouveaux esters de 3,5-dimethylpiperidin-1-ylalkyle |
Non-Patent Citations (10)
Title |
---|
CESKA A SLOVENSKA FARMACIE (1999), 48(4), 170-174, 1999 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; DUBEY, MRIDULA ET AL: "Derivatives of N-aryl-N-aminopiperazines as potential cardiovascular agents", XP002172847, retrieved from STN Database accession no. 96:28278 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SEDLAROVA, E. ET AL: "Studies of physicochemical properties of compounds from the group of 1-(4-phenyl-1-piperazinyl)-3-methoxy-2-propyl 2- and 3-alkoxyphenylcarbamate esters", XP002172832, retrieved from STN Database accession no. 131:228467 CA * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SEGINKO, J. ET AL: "Ca-antagonistic activity of some 1,4-piperazine derivatives", XP002172839, retrieved from STN Database accession no. 123:74205 * |
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SOULIER, JEAN-LOUIS ET AL: "Arylcarbamate Derivatives of 1-Piperidineethanol as Potent Ligands for 5-HT4 Receptors", XP002172873, retrieved from STN Database accession no. 127:272 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CERNUSKOVA, LUCIA ET AL: "3-(4-Phenyl-1-piperazinyl)-2-hydroxy-1-propyl esters of alkoxyphenylcarbamic acids and method for their preparation", XP002172836, retrieved from STN Database accession no. 126:277497 * |
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CERNUSKOVA, LUCIA ET AL: "3-[4-(2-Methoxyphenyl)-1-piperazinyl]-2-hydroxy-1-propyl esters of alkoxyphenylcarbamic acids and method for their preparation", XP002172837, retrieved from STN Database accession no. 126:277496 * |
JOURNAL OF MEDICINAL CHEMISTRY (1997), 40(11), 1755-1761 * |
PHARMAZIE (1995), 50(5), 368-9 * |
POL. J. PHARMACOL. PHARM. (1981), 33(3), 349-57 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004018436A2 (fr) * | 2002-08-23 | 2004-03-04 | Cerep | Composes derives d'arylcarbamates, preparation et utilisations |
WO2004018436A3 (fr) * | 2002-08-23 | 2004-04-15 | Cerep | Composes derives d'arylcarbamates, preparation et utilisations |
Also Published As
Publication number | Publication date |
---|---|
WO2002068399B1 (fr) | 2003-02-20 |
JP2004529106A (ja) | 2004-09-24 |
CA2438828A1 (fr) | 2002-09-06 |
US20040058933A1 (en) | 2004-03-25 |
US7238693B2 (en) | 2007-07-03 |
EP1362041A1 (fr) | 2003-11-19 |
IL157043A0 (en) | 2004-02-08 |
HUP0303253A2 (hu) | 2004-01-28 |
AU2002238688B2 (en) | 2007-07-26 |
FR2821356A1 (fr) | 2002-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3315463B2 (ja) | 環状イミノ誘導体、それらの調製法及びこれらの化合物を含む医薬組成物 | |
EP1373233B1 (fr) | Derives de n-(arylsulfonyl)beta-aminoacides comportant un groupe aminoethyle substitue, leur procede de preparation et les compositions pharmaceutiques en contenant | |
CA2565293C (fr) | Derives de tetrahydroisoquinolilsulfonamides, leur preparation et leur utilisation en therapeutique | |
WO1997025315A1 (fr) | Nouveaux derives de n-(arylsulfonyl)aminoacides ayant une affinite pour les recepteurs de la bradykinine | |
LU85796A1 (fr) | Derives antipsychotiques de la 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine | |
FR2569694A1 (fr) | Derives d'ethylenediaminemonoamide, composition pharmaceutique les contenant et utilisation de ces composes a titre d'antidepresseur ou d'antiparkinsonien | |
AU2005240733A1 (en) | Novel beta agonists, method for producing the same and their use as drugs | |
EP0110781A1 (fr) | (Amino-2 éthyl)-6 benzoxazolinones substituées, leur préparation et une composition pharmaceutique les contenant | |
FR2533564A1 (fr) | Derives de la piperazine presentant une activite anticholinergique et/ou antihistaminique | |
EP1828125B1 (fr) | Derives d'arylpiperazine et leur utilisation comme ligands selectifs du recepteur d3 de la dopamine | |
WO1994015916A1 (fr) | Ligands selectifs des recepteurs 5ht1d-5ht1b derives d'indole-piperazine utiles comme medicaments | |
KR100196985B1 (ko) | 피페리딘 유도체 | |
FR2533563A1 (fr) | Nouveaux derives de la sulfonyluree, leurs procedes de preparation et les compositions pharmaceutiques les renfermant | |
EP0301936B1 (fr) | Dérivés de pipéridine, leur préparation et leur application en thérapeutique | |
WO2002068399A1 (fr) | Derives d'arylcarbamates, preparation et utilisations | |
BG62349B2 (bg) | N-заместени производни на 3-азабицикло/3.2.0/хептан като невролептици | |
WO1999062900A1 (fr) | Derives d'oxindole utile comme antagonistes des recepteurs de neurokinines | |
JPH0395161A (ja) | (1,2,3,4―テトラヒドロ‐9‐アクリジンイミノ)シクロヘキサンカルボン酸および関連化合物 | |
BE1009376A4 (fr) | Derives du carboxymethylidenecycloheptimidazole, procede de preparation de ces derniers et agents therapeutiques contenant ces composes. | |
WO1996026936A1 (fr) | Nouveaux derives de piperazine amino-indole cycliques, leur procede de preparation et leur utilisation a titre de medicaments | |
CA2166470C (fr) | Enantiomeres possedant des proprietes pharmacologiques | |
EP1098888A1 (fr) | Derives de piperazinones et leurs applications | |
FR2639944A1 (fr) | Nouveaux derives de l'indole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
EP1476433B1 (fr) | Nouveaux derives de tricyclo-imidazolines, leur procede de preparation et leur utilisation a titre de medicaments | |
JPS6157582A (ja) | 新規なベンゾジアゼピン類 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: B1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: B1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
B | Later publication of amended claims | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002238688 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 157043 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002704884 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10467932 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2438828 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002567913 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002704884 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002704884 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002238688 Country of ref document: AU |